Where can patients get repeated low-level red-light therapy?

Several manufacturers offer repeated low-level red light (RLRL) products in this innovative field. Each of these devices typically operates under similar principles—delivering specific wavelengths of red light to the retina to help control the elongation of the eye that contributes to myopia. However, the light design, user interface, and additional features such as treatment session tracking, parental controls and regulatory approvals can differ. Here's a summary of the devices used in clinical researches up till now:

Eyerising (Suzhou Xuanjia Optoelectronics Technology, China): This device emits a wavelength of 650nm at a laser power of 0.29mW and was used in 16 studies in diverse groups, including children with pre-myopia, non-highly myopia and high myopia(12,13,16–19,23–32) . It is designed for at-home use, requiring only 3 minutes of use, twice a day, with at least a 4-hour interval between uses.
Longda (Jilin Londa Optoelectronics Technology, China): This device has a laser power of 0.35 mW. It was used in 2 studies which utilized wavelengths of 635 nm(33) and 650 nm(34), respectively.
Sky-n1201 (Beijing Ming Ren Shi Kang Science and Technology, China): This device emits a wavelength of 650nm, and was used in a study that investigated the effect of RLRL at three different power levels (0.37mW, 0.60mW and 1.20mW)(35).
Myopia and Amblyopia Treatment Device (Hunan EnVan Technology, China): This device emits a wavelength of 650nm, and was used in 4 studies(36–39).
Leshi Yangguang (Chenzhou Eye Care Health Technology, China): The device emits a wavelength of 650nm at a laser power of 0.85mW, and was used in 1 study(40).
Airdoc Seconee (Beijing Airdoc Technology, China): This device emits a wavelength of 650nm at different power levels (0.30mW and 1.20mW), and was used in 1 study(41).
Unnamed Device (Hunan New Vision Medical Technology): The device emits a wavelength of 650nm at a laser power of 0.16mW, and was used in 1 study(42).
Unnamed Device (Ya Kun Optoelectronic, China): This device emits a wavelength of 650nm at a laser power of 0.29mW, and was used in 1 study(43).
Unnamed device (VY Optoelectronics, China): This device emits a wavelength of 635nm at a laser power of 0.40mW, and was used in 1 study(44).

Considerations for Use

While red-light therapy shows potential in myopia management, it is crucial to consult with an eye care professional to determine its suitability based on individual eye conditions. To get the best results from RLRL therapy:

Compliance: Try to use the device every day without fail. Consistency is key—using the device as directed can help ensure the therapy works as intended.
Monitoring: Keep an eye on how long any afterimages last after each session. If they last longer than 5 minutes or any other unusual symptoms were found, stop using the device and consult with an eye care professional.
Habit Formation: While children don't need to use the device at the exact same times each day, helping them to establish a routine with the device, especially in the first few week scan be better. It's also important to space out sessions by at least four hours. This allows the eyes adequate time to rest and adjust between treatments.
Wearing Glasses: Continue to wear the glasses or contact lenses as prescribed. RLRL therapy is intended to slow the progression of myopia, not to replace corrective lenses.

RLRL therapy is a promising treatment for myopia control, but it's not a standalone solution. It works best when used in conjunction with regular eye care, including wearing corrective lenses and having regular check-ups with your eye care professional. As with any medical treatment, it's important to follow the guidance of healthcare professionals to ensure the safety and effectiveness of the therapy.

References

12. Jiang Y, Zhu Z, Tan X, Kong X, Zhong H, Zhang J, et al. Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children. Ophthalmology. 2022 May;129(5):509–19.
13. Xiong R, Zhu Z, Jiang Y, Kong X, Zhang J, Wang W, et al. Sustained and rebound effect of repeated low‐level red‐light therapy on myopia control: A 2‐year post‐trial follow‐up study. Clin Experiment Ophthalmol. 2022 Dec;50(9):1013–24.
16. He X, Wang J, Zhu Z, Xiang K, Zhang X, Zhang B, et al. Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial. JAMA Netw Open. 2023 Apr 26;6(4):e239612.
17. Xu Y, Cui L, Kong M, Li Q, Feng X, Feng K, et al. Repeated Low-Level Red Light Therapy for Myopia Control in High Myopia Children and Adolescents. Ophthalmology. 2024 Jun;S016164202400318X.
18. Xiong R, Wang W, Tang X, He M, Hu Y, Zhang J, et al. Myopia Control Effect of Repeated Low-Level Red-Light Therapy Combined with Orthokeratology. Ophthalmology. 2024 May;S0161642024003087.
19. Zhu M, Liu Y, Fang D, Li M, Fu T, Yao K, et al. Safety of repeated low-level red-light therapy for children with myopia. Photodiagnosis Photodyn Ther. 2024 Jun;47:104198.
23. Liu L, Wang Y, Liu F, Yu X, Xie L, Tan S, et al. Effects of repeated low-level red-light therapy on macular retinal thickness and microvascular system in children with myopia. Photodiagnosis Photodyn Ther. 2024 Feb;45:103938.
24. Yu M, Tang X, Jiang J, Zhou F, Wang L, Xiang C, et al. Axial Length Shortening after Combined Repeated Low‐Level Red‐Light Therapy in Poor Responders of Orthokeratology in Myopic Children. García Ayuso D, editor. J Ophthalmol. 2024 Jan;2024(1):4133686.
25. Dong J, Zhu Z, Xu H, He M. Myopia Control Effect of Repeated Low-Level Red-Light Therapy in Chinese Children. Ophthalmology. 2023 Feb;130(2):198–204.
26. Chen Y, Xiong R, Chen X, Zhang J, Bulloch G, Lin X, et al. Efficacy Comparison of Repeated Low-Level Red Light and Low-Dose Atropine for Myopia Control: A Randomized Controlled Trial. Transl Vis Sci Technol. 2022 Oct 21;11(10):33.
27. Liu Z, Sun Z, Du B, Gou H, Wang B, Lin Z, et al. The Effects of Repeated Low-Level Red-Light Therapy on the Structure and Vasculature of the Choroid and Retina in Children with Premyopia. Ophthalmol Ther. 2024 Mar;13(3):739–59.
28. Liu G, Li B, Rong H, Du B, Wang B, Hu J, et al. Axial Length Shortening and Choroid Thickening in Myopic Adults Treated with Repeated Low-Level Red Light. J Clin Med. 2022 Dec 17;11(24):7498.
29. Liu G, Rong H, Liu Y, Wang B, Du B, Song D, et al. Effectiveness of repeated low-level red light in myopia prevention and myopia control. Br J Ophthalmol. 2024 Sep;108(9):1299–305.
30. Lin ZH, Tao ZY, Kang ZF, Deng HW. A Study on the Effectiveness of 650-nm Red-Light Feeding Instruments in the Control of Myopia. Ophthalmic Res. 2023;664–71.
31. Zhao C, Ni Y, Zeng J. Effect of red‐light therapy on retinal and choroidal blood perfusion in myopic children. Ophthalmic Physiol Opt. 2023 Nov;43(6):1427–37.
32. Wang W, Jiang Y, Zhu Z, Zhang S, Xuan M, Chen Y, et al. Clinically Significant Axial Shortening in Myopic Children After Repeated Low-Level Red Light Therapy: A Retrospective Multicenter Analysis. Ophthalmol Ther. 2023 Apr;12(2):999–1011.
33. Chen H, Wang W, Liao Y, Zhou W, Li Q, Wang J, et al. Low-intensity red-light therapy in slowing myopic progression and the rebound effect after its cessation in Chinese children: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol. 2023 Feb;261(2):575–84.
34. Zhou L, Tong L, Li Y, Williams BT, Qiu K. Photobiomodulation therapy retarded axial length growth in children with myopia: evidence from a 12-month randomized controlled trial evidence. Sci Rep. 2023 Feb 27;13(1):3321.
35. Zhou W, Liao Y, Wang W, Sun Y, Li Q, Liu S, et al. Efficacy of Different Powers of Low-Level Red Light in Children for Myopia Control. Ophthalmology. 2024 Jan;131(1):48–57.
36. Cao K, Tian L, Ma DL, Zhao SQ, Li A, Jin ZB, et al. Daily Low-Level Red Light for Spherical Equivalent Error and Axial Length in Children With Myopia: A Randomized Clinical Trial. JAMA Ophthalmol. 2024 Jun 1;142(6):560.
37. Tian L, Cao K, Ma DL, Lu LX, Zhao SQ, Li A, et al. Six-month repeated irradiation of 650 nm low-level red light reduces the risk of myopia in children: a randomized controlled trial. Int Ophthalmol. 2023 Jun 15;43(10):3549–58.
38. Tian L, Cao K, Ma DL, Zhao SQ, Lu LX, Li A, et al. Investigation of the Efficacy and Safety of 650 nm Low-Level Red Light for Myopia Control in Children: A Randomized Controlled Trial. Ophthalmol Ther. 2022 Dec;11(6):2259–70.
39. Zhang H, Cui M, Jie Y, Chen T, Kang M, Bai W, et al. Efficacy of repeated low-level red-light therapy in the prevention and control of myopia in children. Photodiagnosis Photodyn Ther. 2024 Jun;47:104216.
40. Shang L, Gao S, Wang W, Chang M, Ma N, Huang C, et al. Comparison of Changes in Retinal Vascular Density and Thickness After Using Low-Level Red Light and 0.01% Atropine in Premyopic Children. Transl Vis Sci Technol. 2024 Jun 28;13(6):23.
41. Qiu K, David C, Li Y, Lei Z, Tong L, Lin W. A retrospective study of cumulative absolute reduction in axial length after photobiomodulation therapy. BMC Ophthalmol. 2024 Apr 25;24(1):191.
42. Yang W, Lin F, Li M, Wei R, Zhou J, Zhou X. Immediate Effect in the Retina and Choroid after 650 nm Low-Level Red Light Therapy in Children. Ophthalmic Res. 2023;66(1):312–8.
43. Xiong F, Mao T, Liao H, Hu X, Shang L, Yu L, et al. Orthokeratology and Low-Intensity Laser Therapy for Slowing the Progression of Myopia in Children. Napoli PE, editor. BioMed Res Int. 2021 Jan 27;2021:1–10.
44. Zhou L, Xing C, Qiang W, Hua C, Tong L. Low‐intensity, long‐wavelength red light slows the progression of myopia in children: an Eastern China‐based cohort. Ophthalmic Physiol Opt. 2022 Mar;42(2):335–44.